Glioblastoma Program
Glioblastoma
Discovery/Pre-clinicalActive
Key Facts
About Purposeful
Purposeful is an early-stage biotech leveraging an AI platform to identify new therapeutic uses for existing, approved drugs, with a primary focus on rare genetic diseases. The company has established research collaborations with patient foundations and pharmaceutical companies to validate candidates for conditions like Fragile X Syndrome and Glioblastoma. Operating as a private, likely pre-revenue entity, Purposeful aims to significantly reduce the time and cost of drug development by bypassing early-stage safety testing.
View full company profileTherapeutic Areas
Other Glioblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Ropidoxuridine (IPdR) | Shuttle Pharmaceuticals | Phase 2 |
| LNTH-2505 | Lantheus Medical Imaging | Preclinical |
| Leronlimab | CytoDyn | Preclinical |
| Glioblastoma Moonshot | Owkin | Research |
| OPC-001 (PDC Candidate) | Oncopeptides | Phase 1/Window-of-Opportunity |
| αvβ3-targeted ADC | Xintela | Preclinical |
| Undisclosed | Biossil | Phase 2/3 |
| GLIX1 | Hemispherian | Phase 1 |
| InC01 | InCephalo Therapeutics | Pre-clinical |
| Glioblastoma Combination Therapy | JLP Health | Pre-clinical |
| ENV105 | Kairos Pharma | IND Cleared |
| LMP744 | Gibson Oncology | Phase 2 |